Loading
A folate-receptor ADC designed to work across low and high receptor levels, in a pivotal ovarian cancer trial.
Sutro Biopharma's site-specifically conjugated FRα ADC. Phase 1 showed responses in FRα-low as well as FRα-high tumours; the phase 2/3 REFRαME-O1 trial in platinum-resistant ovarian cancer (any FRα expression >25%) is ongoing, with an interim analysis expected in 2026. Neutropenia and arthralgia are characteristic.
Anti-FRα antibody with a hemiasterlin microtubule inhibitor conjugated at defined non-natural amino acids. Connects to Folate receptor alpha.
1.Luveltamab tazevibulin's antibody arm binds Folate receptor alpha on the surface of the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Luveltamab tazevibulin" OR ABSTRACT:"Luveltamab tazevibulin" OR TITLE:"STRO-002" OR ABSTRACT:"STRO-002") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Luveltamab tazevibulin, not a curated reading list.
Shares Folate receptor alpha, Advanced or recurrent endometrial cancer, Platinum-resistant ovarian cancer, Endometrial cancer.
Shares Sequence folate-receptor ADCs by payload class, Folate receptor alpha, Advanced or recurrent endometrial cancer, Platinum-resistant ovarian cancer.
Shares Folate receptor alpha, Platinum-resistant ovarian cancer, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Folate receptor alpha, Platinum-resistant ovarian cancer, Endometrial cancer, Ovarian cancer.
Shares Platinum-resistant ovarian cancer, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Ovarian cancer.
Shares Sequence folate-receptor ADCs by payload class, Platinum-resistant ovarian cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Ovarian cancer.